Plain-English translation of NCT07558083 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new approach to treating advanced colorectal cancer using liquid biopsy—a special blood test that detects cancer DNA. Instead of relying only on CT scans to decide when to change treatment, doctors in one group will use these blood tests to spot cancer growth earlier and adjust therapy sooner. The goal is to help you stay on effective treatment longer while avoiding drugs that aren't working.
Standard CT scans sometimes detect cancer growth too late, which means patients may receive ineffective treatment longer than necessary and experience unnecessary side effects. This trial wants to see if blood tests can catch disease progression earlier, allowing doctors to switch treatments faster and protect your quality of life.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups: one group will have treatment decisions guided by standard CT scans (the usual approach), and the other group will have decisions guided by regular blood tests. Both groups will be followed for 18 months. You'll have regular blood draws and imaging scans according to the study schedule, and your doctors will adjust your treatment based on either CT results or blood test results, depending on which group you're in.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Belgium